Deloitte China assists secondary listing of China Medical System on SGX
Secondary listing of a China-based pharmaceutical company in Singapore
Deloitte China assisted the secondary listing of China Medical System Holdings (China Medical System; SEHK stock code: 00867.HK; SGX ticker symbol: CMS) on the Singapore Exchange (SGX) on 15 July 2025. This is a secondary listing by a China-based pharmaceutical company based in Singapore.
Upon completing this secondary listing, China Medical System will remain listed on the Stock Exchange of Hong Kong (SEHK), enabling the company to geographically diversify its shareholder base, build its profile and provide more different market choices for trading in its shares.
(From Left) Laura Luo, independent non-executive director of China Medical System; Jack Li, Southern Region Offering Services partner of Deloitte China's Capital Market Services Group; Chen Yanling, executive director, chief financial officer and vice president of China Medical System; Sunnie Sy, Southern Region Offering Services partner of Deloitte China's Capital Market Services Group; and Sammy Lee, general manager of China Medical System's Finance Center, attend China Medical System's listing ceremony at SGX.
All representatives from the intermediatory organizations that were involved in this secondary listing of China Medical System, including from CGS International Securities Singapore, WongPartnership LLP, Zhong Lun Law Firm, Allen Overy Shearman Sterling, Drew & Napier LLC, Jingtian & Gongcheng, and Deloitte China pose at the China Medical System listing ceremony at SGX.
All the representatives from China Medical System and intermediatory organisations pose at the China Medical System listing ceremony at SGX.
Client overview
China Medical System is a platform company linking pharmaceutical innovation and commercialisation with full product lifecycle management capability, dedicated to providing products and services to meet unmet healthcare needs.
The company has been listed on the SEHK since 2020. As of 9 July 2025, China Medical System’s market capitalisation was HKD30.5 billion.
Deloitte’s role
When China Medical System listed on the SEHK, Deloitte China was its reporting accountant. We became its auditor after the listing. Over the years, Deloitte China has been dedicated in providing high quality service to the client.
As one of the core service institutes of this secondary listing work for China Medical System, Deloitte China was deeply involved in the entire process, together with Deloitte Singapore. Our engagement team maintained a dedicated, diligent attitude with a high-quality philosophy of diligence and excellence. We delivered the highest quality of professional services using our rich industry experience to assist China Medical System to complete its filing work smoothly at every stage of the secondary Iisting. We also cooperated with related professional parties to complete this secondary listing for China Medical System on SGX.
Deloitte China congratulates China Medical System on its successful secondary listing on the SGX. We will continue to provide high quality professional services and outstanding resources integration to assist more clients to take one-step ahead in today's increasingly competitive and complex business environment.
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited (“DTTL”), its global network of member firms, and their related entities (collectively, the “Deloitte organization”). DTTL (also referred to as “Deloitte Global”) and each of its member firms and related entities are legally separate and independent entities, which cannot obligate or bind each other in respect of third parties. DTTL and each DTTL member firm and related entity is liable only for its own acts and omissions, and not those of each other. DTTL does not provide services to clients. Please see About Deloitte to learn more.
Deloitte China provides integrated professional services, with our long-term commitment to be a leading contributor to China’s reform, opening-up and economic development. We are a globally connected firm with deep roots locally, owned by our partners in China. With over 20,000 professionals across 31 Chinese cities, we provide our clients with a one-stop shop offering world-leading audit, tax and consulting services.
We serve with integrity, uphold quality and strive to innovate. With our professional excellence, insight across industries, and intelligent technology solutions, we help clients and partners from many sectors seize opportunities, tackle challenges and attain world-class, high-quality development goals.
The Deloitte brand originated in 1845, and its name in Chinese (德勤) denotes integrity, diligence and excellence. Deloitte's global professional network of member firms now spans more than 150 countries and territories. Through our mission to make an impact that matters, we help reinforce public trust in capital markets, enable clients to transform and thrive, empower talents to be future-ready, and lead the way toward a stronger economy, a more equitable society and a sustainable world.
This communication contains general information only, and none of Deloitte Touche Tohmatsu Limited (“DTTL”), its global network of member firms or their related entities (collectively, the “Deloitte organization”) is, by means of this communication, rendering professional advice or services. Before making any decision or taking any action that may affect your finances or your business, you should consult a qualified professional adviser.
No representations, warranties or undertakings (express or implied) are given as to the accuracy or completeness of the information in this communication, and none of DTTL, its member firms, related entities, employees or agents shall be liable or responsible for any loss or damage whatsoever arising directly or indirectly in connection with any person relying on this communication. DTTL and each of its member firms, and their related entities, are legally separate and independent entities.
